We are excited to introduce our latest venture in the NLC portfolio, Neurolieve Biosciences Ltd. This new biotech venture is developing an innovative treatment aimed at improving the lives of those suffering from neuropathic pain. Neurolieve's therapy, exclusively licensed from LifeArc, was developed by scientists at LifeArc’s drug discovery labs in collaboration with Professor David Wynick at the University of Bristol. Led by CEO, Massimo Mineo, Neurolieve Biosciences is at the forefront of innovation in treating neuropathic pain, setting new standards in the field! #innovation #bringsciencetolife #healthtech #NLC
Neurolieve Biosciences Ltd
Biotechnology Research
A new-biotech company focused on the development of an innovative drug for the treatment of peripheral neuropathic pain
About us
Neurolieve Biosciences is a biotech company backed by NLC Health Ventures, developing an innovative, bioengineered protein-based therapy designed to target the root causes of neuropathic pain. This novel treatment works by specifically interacting with nerve cells of pain-sensing systems to decrease pain sensitivity, yet without the common side effects of current medications.
- Website
-
www.neurolievebiosciences.com
External link for Neurolieve Biosciences Ltd
- Industry
- Biotechnology Research
- Company size
- 1 employee
- Type
- Privately Held
- Founded
- 2024